This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Hemophilia CC형혈우병 (씨형혈우병)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D68.1 (hereditary factor XI deficiency) | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsHereditary factor XI deficiency, Rosenthal syndrome, PTA deficiency, Factor XI deficiency, Rosenthal's disease
C. Adult onsetLikelihood of first onset in adulthood very high — because spontaneous joint bleeding is rare in hemophilia C, diagnosis is easily missed in childhood, and discovery through abnormal bleeding at a first surgery, tooth extraction, or delivery in adulthood accounts for more than half of all diagnoses; plasma FXI activity and clinical bleeding severity are not necessarily proportional, so some patients remain asymptomatic for life even with FXI:C near 0.
1. History1953 first report of PTA deficiency by Rosenthal. The emergence of the name "hemophilia C" and the subsequent course of naming controversy among experts.
2. CausesPathogenic variants in the F11 gene at 4q35.2 on chromosome 4; autosomal recessive inheritance; high frequency of the Ashkenazi Jewish founder variants E117X and F283L.
3. GeneticsF11 gene at 4q35.2, 15 exons, mature protein of 607 amino acids (80 kDa homodimer). Autosomal recessive → affects men and women equally; a fundamental difference from hemophilia A and B (X-linked).
4. EpidemiologyPrevalence of severe deficiency about 1/1,000,000 in the general population; about 1/450 among Ashkenazi Jews (heterozygous carriers about 8%). Male-to-female ratio 1:1.
5. PathophysiologyFXI deficiency → weakened thrombin feedback loop → insufficient amplification of intrinsic tenase → early breakdown of hemostatic clots at mucosal sites with high fibrinolytic activity.
6. SymptomsDecisive differences from hemophilia A and B: spontaneous joint bleeding and muscle hematomas are rare; excessive bleeding at surgery, tooth extraction, trauma, or delivery is the main symptom; menorrhagia and postpartum hemorrhage in women; FXI:C not proportional to bleeding severity.
7. SignsIsolated APTT prolongation, decreased FXI:C, normal PT, TT, platelets, and bleeding time. Inhibitors are rare but may develop after repeated administration of FXI concentrates.
8. ScreeningIncidental discovery from preoperative APTT prolongation; family screening; screening programs in Ashkenazi Jewish populations; use of a bleeding assessment tool (ISTH-BAT).
9. DiagnosisAPTT prolongation → mixing test → single-factor FXI:C measurement → differentiation from FXII, PK, and HMW kininogen → FXI:Ag measurement (type I/II classification) → F11 gene analysis.
10. TreatmentFFP (fresh frozen plasma), FXI concentrates (some European countries), tranexamic acid, DDAVP (limited effect); individualized approach based on bleeding history; bypassing agents (rFVIIa/aPCC) if inhibitors develop.
11. PrognosisNormal life expectancy. Chronic complications of hemophilia A and B, such as arthropathy and muscle atrophy, are rare. Most complications can be prevented with prior diagnosis and surgical planning.
12. PreventionGenetic counseling, family screening, hematology consultation before surgery and procedures, prophylactic tranexamic acid, caution with aspirin and NSAIDs, carrying a medical alert card.
13. ReferencesRosenthal RL et al. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med. 1953 … and 11 other papers

1. History

Rosenthal's 1953 report and the birth of "hemophilia C"

The paper published in 1953 by Robert L. Rosenthal, Oscar H. Dreskin, and Norman Rosenthal of the USA in the Proceedings of the Society for Experimental Biology and Medicine is recorded in the history of coagulation medicine as the first study to describe a third type of bleeding disease distinct from hemophilia A and B. They discovered a new coagulation deficiency that showed APTT prolongation similar to hemophilia but was mutually corrected by the plasma of patients with hemophilia A or hemophilia B, and named the deficient factor Plasma Thromboplastin Antecedent (PTA). This discovery helped establish that hemophilia is not a single disease but a group of multiple independent diseases by coagulation factor. Thereafter, this new deficiency disease began to be popularly called Hemophilia C, meaning the third "hemophilia" after hemophilia A and B.

Debate over the appropriateness of the name "hemophilia C"

The name "hemophilia C" has long been a subject of debate among clinicians. The core of the opposing view is that there are essential clinical, genetic, and pathophysiological differences between classic hemophilia (hemophilia A and B) and hemophilia C, and that grouping them under the same name "hemophilia" causes clinical confusion. First, hemophilia A and B show X-linked recessive inheritance, whereas hemophilia C shows autosomal recessive inheritance and affects women equally. Second, in hemophilia A and B there is a relatively clear correlation between plasma coagulation factor activity and bleeding severity, whereas in hemophilia C this correlation is very unclear. Third, spontaneous joint bleeding (hemarthrosis) and muscle hematomas, the main symptoms of hemophilia A and B, are rare in hemophilia C, where bleeding after surgery at mucosal sites is instead the main clinical problem. For these reasons, many hematologists prefer to call this disease "Hereditary factor XI deficiency" or "Rosenthal syndrome."

Establishment of the name and international classification

Official documents of the International Society on Thrombosis and Haemostasis (ISTH) and the World Federation of Hemophilia (WFH) refer to this disease as Factor XI deficiency, and the trend is not to recommend use of the name "hemophilia C." In clinical practice, however, the name "hemophilia C" is still used in patient education, hemophilia patient support organizations, and some textbooks. In the World Health Organization (WHO) ICD-10 classification, the disease is coded as D68.1 (hereditary factor XI deficiency), and "hemophilia C" is listed as a synonym. The WFH officially classifies it as one of the "Rare Bleeding Disorders (RBD)" and does not include it in the same "hemophilia" category as hemophilia A and B. Because this diversity of names can cause confusion in clinical records and patient education, physicians should be familiar with both names and explain them clearly to patients.

FXI rediscovered as an antithrombotic target: new medical importance beyond the naming debate

Hemophilia C/hereditary factor XI deficiency, which received relatively little attention until the late 20th century, began to attract medical interest from a new angle in the 21st century. Epidemiological observations accumulated that higher FXI levels increase the risk of venous thromboembolism and ischemic stroke, and conversely there were reports that venous thrombosis is less frequent in patients with hereditary factor XI deficiency. This suggested that FXI plays a dual role, contributing to thrombus formation while also being important for hemostasis. In 2015, results of a phase 2 clinical trial were published showing that an antisense oligonucleotide targeting FXI mRNA (ISIS 416858, now fesomersen) provided similar thromboprophylactic efficacy with a lower bleeding risk than standard anticoagulants in orthopedic surgery patients. Subsequently, various FXI/FXIa inhibitors, including abelacimab, osocimab, asundexian, and milvexian, entered clinical trials with indications such as atrial fibrillation, stroke, and thromboprophylaxis after orthopedic surgery, and a paradoxical situation is unfolding in which molecular research on hemophilia C/hereditary factor XI deficiency has become the cornerstone for developing new antithrombotic drugs.


2. Causes

F11 gene variants and mode of inheritance

Hemophilia C is caused by pathogenic variants in the F11 gene located at 4q35.2 on the long arm of chromosome 4. The F11 gene spans a genomic region of about 23 kb and consists of 15 exons. The mode of inheritance is autosomal recessive, which differs fundamentally from the X-linked recessive hemophilia A (F8, Xq28) and hemophilia B (F9, Xq27.1). Because of autosomal recessive inheritance, men and women are affected equally, and severe deficiency appears only when a variant allele is inherited from each parent (homozygous or compound heterozygous). When only one parent is a carrier—the heterozygous state—FXI:C is mildly reduced to about 40–60% of normal, and even at this level some patients may have increased bleeding after surgery or tooth extraction.

Comparison with hemophilia A and B: differences in the causative factor

Comparing hemophilia A, B, and C at the level of the causative factor: hemophilia A is a deficiency of coagulation factor VIII (FVIII, a 280 kDa glycoprotein), and the F8 intron 22 inversion is a frequent variant mechanism accounting for about 45% of all severe hemophilia A. Hemophilia B is a deficiency of coagulation factor IX (FIX, a 55 kDa vitamin K-dependent protein), with various point mutations as the main variant type. Hemophilia C is a deficiency of coagulation factor XI (FXI, an 80 kDa serine protease homodimer); in Ashkenazi Jews, two founder variants, E117X and F283L, account for most cases, while various variants are distributed in non-Ashkenazi populations. FXI activates FIX in the intrinsic coagulation pathway, but it is also distinguished from the mechanisms of hemophilia A and B in that its main activation route in the body is feedback by early thrombin rather than FXIIa.

Founder effect in Ashkenazi Jews

The most characteristic phenomenon in the epidemiology of hemophilia C is its high frequency in the Ashkenazi Jewish (Eastern European Jewish) population. In this population, the heterozygous carrier frequency is about 8% (about 1 in 12–13), and the prevalence of severe deficiency reaches about 1/450. This is understood to result from F11 variant alleles in the founder population being rapidly fixed and spread by genetic drift within closed Jewish communities several hundred years ago. The two most common founder variants identified in this population are the Glu117Ter (E117X) nonsense variant in exon 5 (premature protein termination → nonsense-mediated mRNA decay, so almost no FXI protein is produced) and the Phe283Leu (F283L) missense variant in exon 9 (impaired dimer assembly → reduced plasma FXI secretion). These two variants alone account for more than about 90% of Ashkenazi Jewish patients with hemophilia C.

Functional consequences: absent or reduced FXI activity

The effect on FXI protein and activity differs by type of variant. In type I deficiency (CRM−), both FXI activity (FXI:C) and FXI antigen (FXI:Ag) are reduced. This applies when protein synthesis itself is reduced by nonsense variants such as E117X or large deletions, or when dimer assembly is disrupted, as with F283L, greatly reducing secretion into plasma. In type II deficiency (CRM+), FXI antigen is normal or near normal but functional activity is reduced. This is the case when missense variants located in the active site, substrate (FIX)-binding site, or cofactor (FVIIIa)-binding site allow the FXI molecule to be synthesized and secreted but impair its enzymatic function. Clinically, both types can show a similar bleeding tendency, but distinguishing type II in the laboratory requires measuring both FXI:C and FXI:Ag.


3. Genetics

Genetic comparison of hemophilia A, B, and C

Comparing the three types of hemophilia from a genetic standpoint is very important in clinical practice. Hemophilia A (F8, Xq28) and hemophilia B (F9, Xq27.1) are X-linked recessive diseases transmitted from female carriers to male children, and female patients are very rare (exceptions include Turner syndrome, homozygous females, and carriers with unbalanced lyonization). In contrast, hemophilia C (F11, 4q35.2) is located on autosomal chromosome 4, so women can be affected equally with men. This genetic difference leads to fundamental differences in the epidemiology of the disease, genetic counseling, and the approach to prenatal diagnosis. Also, in the X-linked hemophilia A and B, the sons of a female carrier have a 50% chance of being affected, whereas in the autosomal recessive hemophilia C, a 25% chance of being affected applies to the children of a couple who are both carriers.

Structural features of the F11 gene

The F11 gene is located at 4q35.2 on the long arm of chromosome 4, and this position near the chromosome end is being studied as one of the factors affecting gene stability. The gene is about 23 kb in total length and consists of 15 exons, each encoding a specific protein domain. Exons 1–3 encode the signal peptide and propeptide, exons 4–13 separately encode the four apple domains (A1–A4), and exons 13–15 encode the serine protease domain. The F11 gene is also listed in databases under its former name PTA (Plasma Thromboplastin Antecedent). The official HGNC (HUGO Gene Nomenclature Committee) symbol is F11, and its Entrez Gene ID is 2160.

Protein structure and function: apple domains and the dimer

The most distinctive structural feature of the FXI protein is that it exists in plasma as a homodimer. Unlike most coagulation factors, which circulate as monomers, FXI circulates in plasma as a dimer (about 160 kDa in total) of two identical monomers (each about 80 kDa) linked by noncovalent and covalent bonds through a Cys321-Cys321' disulfide bond. Each monomer consists of four N-terminal apple domains (A1-A2-A3-A4) and a C-terminal serine protease domain. The A1 domain is involved in dimer formation and HMW kininogen binding; the A2 domain forms the environment adjacent to the activation cleavage site for FXIIa and thrombin; the A3 domain contains the site of direct cleavage by FXII and thrombin (Arg369-Ile370); and the A4 domain contains the platelet GPIb-binding site, enabling FXI to be concentrated and activated on the platelet surface. The serine protease domain is responsible for the catalytic activity that cleaves the substrate FIX, with the catalytic triad (His413-Asp462-Ser557) at its core. This unique dimeric structure is important for explaining the diversity of molecular dysfunction caused by F11 variants.

Clinical relevance in carrier females

Because inheritance is autosomal recessive, heterozygous carrier females of hemophilia C have a different clinical significance from carrier females of X-linked hemophilia. Even heterozygous carrier females with FXI:C reduced to about 40–60% of normal may have increased bleeding at surgery, tooth extraction, or delivery, and there are reports of a significant increase in menorrhagia. Heterozygous carrier males may also show the same degree of FXI:C reduction and a mild increase in bleeding tendency. Therefore, preoperative FXI:C testing is recommended for all heterozygous parents and siblings of patients diagnosed with hemophilia C. This contrasts with X-linked hemophilia A and B, in which only carrier females are clinically significant.


4. General epidemiology

Prevalence and incidence

The severe form of hemophilia C (hereditary factor XI deficiency) (FXI:C <20%) is a rare disease with a prevalence of about 1 per million in the general population. However, because spontaneous bleeding is rare, diagnosis is often delayed or missed, and the actual prevalence is thought to be higher. The prevalence of all FXI deficiency including heterozygous carriers (including mild cases) is estimated at about 1 per 100,000 or more. According to the World Federation of Hemophilia (WFH) 2023 Annual Global Survey, about 35,000 patients with FXI deficiency are officially registered worldwide, but this is thought to reflect only a fraction of actual patients.

Epidemiological differences from hemophilia A and B

Hemophilia A has an incidence of about 1 in 5,000 male births and hemophilia B about 1 in 25,000–30,000 male births, making them X-linked diseases concentrated in males. In contrast, hemophilia C (hereditary factor XI deficiency) is autosomal recessive, with a male-to-female ratio of 1:1. However, its absolute prevalence is much lower than that of hemophilia A. Hemophilia A and B show relatively uniform prevalence worldwide, but hemophilia C shows a uniquely high frequency in Ashkenazi Jews, so prevalence varies greatly by region and ethnicity. This uneven ethnic distribution is due to a founder effect, and Israel's share of registered hemophilia C patients is particularly high relative to the number of registered patients worldwide.

Status in Korea

In Korea, far fewer patients with hemophilia C are registered than with hemophilia A or B, and the number of registered FXI deficiency patients identified from Korea Hemophilia Foundation and Health Insurance Review & Assessment Service (HIRA) data is estimated at several dozen. Because there is almost no Ashkenazi Jewish population in Korea, Korean patients are more likely to have various F11 variants specific to Korea than Ashkenazi founder variants such as E117X and F283L. As next-generation sequencing (NGS) has been introduced into Korean clinical laboratories, F11 variants are increasingly being identified in cases of atypical APTT prolongation, but a systematic national registration and follow-up system is not yet in place.

Epidemiological relationship with thrombosis

Epidemiological studies have consistently reported a positive correlation between FXI levels and thrombosis risk. In a Dutch study by Meijers et al. (2000), people with FXI levels at or above the 90th percentile had about a 2.2-fold increased risk of venous thromboembolism. Conversely, there are reports of reduced venous thrombosis in patients with hemophilia C, while a protective effect against myocardial infarction has not been consistently observed. The relationship between ischemic stroke and FXI has also been studied, with data showing that higher FXI levels increase stroke risk and that stroke is reduced in patients with FXI deficiency. This bidirectional epidemiological relationship is important evidence supporting the potential of FXI as an "antithrombotic target without bleeding."


5. Pathophysiology

The classic intrinsic pathway and the position of FXI

In the traditional coagulation cascade model, coagulation factor XI (FXI) is a component of the intrinsic pathway (contact activation pathway) and is activated to FXIa by activated factor XII (FXIIa). FXIa cleaves FIX in the presence of Ca²⁺ to produce FIXa, and FIXa forms the intrinsic tenase complex, composed of FVIIIa, Ca²⁺, and phospholipid, which converts FX to FXa. FXa, common to the extrinsic and intrinsic pathways, forms the prothrombinase complex with FVa, Ca²⁺, and phospholipid, converting prothrombin (FII) to thrombin (FIIa). Thrombin converts fibrinogen to fibrin to form a fibrin clot, completing hemostasis. In FXI deficiency, the early steps of this pathway are weakened, FIXa generation decreases, and as a result thrombin generation becomes insufficient.

Activation of FXI by thrombin on the platelet surface: the core of feedback amplification

However, clinical observations show that the classic intrinsic pathway model alone cannot readily explain the pathophysiology of hemophilia C. It has been established that patients with FXII deficiency, prekallikrein deficiency, or HMW kininogen deficiency have no clinical bleeding despite markedly prolonged APTT. This suggests that the main route of FXI activation in vivo does not depend on FXII. According to the current cell-based model of hemostasis, the key is a thrombin feedback amplification mechanism in which FXIa is generated as FXI dimers bound to GPIb on the platelet surface are directly cleaved and activated by early thrombin (the small amount of thrombin generated via the TF-FVIIa pathway). This FXIa further activates FIX on the platelet surface, inducing generation of large amounts of thrombin (thrombin burst), and at the same time activates TAFI (thrombin-activatable fibrinolysis inhibitor), protecting the formed fibrin clot from fibrinolysis.

Selective hemostatic vulnerability in FXI deficiency: sites of fibrinolytic activity

Spontaneous joint and muscle bleeding is rare in hemophilia C because early thrombin generation via the tissue factor pathway (extrinsic pathway) is preserved. After vascular injury, exposed tissue factor-FVIIa generates small amounts of FIXa and FXa, which trigger platelet activation and early thrombin generation, so primary hemostasis (platelet plug formation) proceeds normally. This early thrombin alone allows sufficient hemostasis in deep tissues. However, at sites with very high fibrinolytic activity—the oral and pharyngeal mucosa, nasal cavity, genitourinary mucosa such as the renal pelvis, ureters, and bladder, and the endometrium—without thrombin feedback amplification, TAFI activation is insufficient, so the formed fibrin clot is rapidly dissolved by tissue plasminogen activators (tPA, uPA), and hemostatic failure therefore recurs. This is why delayed bleeding after tooth extraction, bleeding after tonsillectomy, hematuria after urologic surgery, bleeding after uterine procedures, and menorrhagia are prominent in patients with hemophilia C.

Mechanisms of the discordance between FXI:C and clinical bleeding

The discordance between FXI:C and bleeding phenotype, a characteristic unique to hemophilia C, can be explained by several mechanisms. First, small amounts of FXI are also stored within platelets, and platelet FXI content may influence the effective FXIa concentration at the site of vascular injury, which may differ between individuals. Second, the activity of the fibrinolytic system varies considerably between tissues and between individuals, so at the same FXI:C, individuals in whom fibrinolysis is better suppressed may bleed less. Third, variants in other coagulation and fibrinolysis genes, such as TAFI polymorphisms, may modulate the bleeding phenotype of FXI deficiency. Fourth, the unusually low FXI:C measured in some heterozygous carriers may be due to a rare variant on the second allele or a random imbalance of expression similar to an incomplete lyonization effect.


6. Symptoms

Decisive clinical differences from hemophilia A and B

The clinical feature that most clearly distinguishes hemophilia C from hemophilia A and B is the rarity of spontaneous deep tissue bleeding. In patients with severe hemophilia A or B, recurrent spontaneous joint bleeding (hemarthrosis) destroys articular cartilage and synovium and progresses to hemophilic arthropathy, and recurrent muscle hematomas cause serious chronic complications such as the formation of pseudotumors. In contrast, even in severe hemophilia C (FXI:C <20%), spontaneous joint and muscle bleeding is extremely rare, and resulting arthropathy or muscle complications almost never occur. This fundamental clinical difference is one of the main reasons many experts object to calling hemophilia C a "hemophilia." Patients lead normal physical activity and lives in daily settings without special hemostatic stress, and for this reason it is common for them to spend a long time unaware that they have a bleeding disorder.

Characteristics of bleeding provoked by surgery and procedures

The clinically most important type of bleeding in hemophilia C is delayed bleeding after surgery or invasive procedures. This bleeding characteristically often begins not immediately after surgery but 24–48 hours or more after it, consistent with the mechanism by which the initial fibrin clot gradually dissolves over time through fibrinolytic activity. Specifically, high-risk procedures by site include tooth extraction (especially wisdom tooth extraction) and oral mucosal procedures in the oral region; tonsillectomy and adenoidectomy in the upper airway; transurethral resection of the prostate (TURP), pyelotomy, and bladder surgery in the genitourinary tract; endometrial biopsy, curettage, and hysterectomy in gynecology; and intra-abdominal surgery (gastrointestinal tract, gallbladder, etc.) in general surgery. In contrast, procedures on limb muscles, joints, or the intracranial space can be performed relatively safely.

Symptoms specific to women

Because hemophilia C is an autosomal disease, women have the same incidence as men, and additional symptoms may appear in women. Menorrhagia is a major symptom reported in about 50–75% of women with hemophilia C; FXI deficiency combined with the high fibrinolytic environment of the endometrium causes prolonged menstrual periods, passage of clots, and excessive blood loss. Without control by tranexamic acid or hormonal agents, it often leads to iron deficiency anemia. The risk of postpartum hemorrhage increases because FXI:C rises slightly physiologically during pregnancy and then falls sharply after delivery. Because an FXI-deficient fetus in utero may also have an increased risk of intracranial hemorrhage from birth trauma, neonatal FXI:C testing should also be included in the plan for pregnant women with FXI deficiency.

Clinical severity assessment based on bleeding history

Because the correlation between FXI:C levels and the clinical bleeding phenotype is unclear in hemophilia C, clinical severity assessment should center on the patient's actual bleeding history rather than coagulation factor activity. Patients with past bleeding at tooth extraction, trauma, surgery, or delivery are at high risk of bleeding in similar or larger procedures in the future. Conversely, patients who have had no abnormal bleeding in past invasive procedures despite severe FXI:C reduction (FXI:C <1 IU/dL) sometimes show a relatively low bleeding tendency. Because of this complexity, systematic recording of bleeding history using bleeding assessment tools such as the ISTH-BAT is essential for clinical decisions.


7. Signs

Coagulation test pattern: isolated APTT prolongation

The most characteristic coagulation test finding in hemophilia C is isolated prolongation of the APTT. In severe FXI deficiency (FXI:C <20%), the APTT is usually prolonged by 10–30 seconds or more beyond the normal control. In heterozygous carriers (FXI:C about 40–60%), the APTT may be mildly prolonged or near the upper limit of normal, and depending on the sensitivity of the APTT reagent, heterozygotes are sometimes classified as normal. In contrast, the prothrombin time (PT) reflects only the extrinsic pathway and is not affected by FXI deficiency, so it is normal. The thrombin time (TT) assesses the fibrinogen-thrombin conversion step and is also normal. Platelet count and bleeding time (BT) are not affected by FXI deficiency itself and are in the normal range. This pattern—prolonged APTT with normal PT/TT/BT/platelets—can be seen in common in deficiencies of intrinsic pathway contact factors (FVIII, FIX, FXI, FXII, PK, HMW kininogen) or with lupus anticoagulant (LA), so additional tests are needed to identify the cause.

FXI-specific test findings

To confirm that FXI deficiency is the cause of APTT prolongation, single-factor FXI assay (one-stage FXI:C assay) is performed. In this test, FXI:C <20 IU/dL is classified as severe deficiency, 20–70 IU/dL as the mild to heterozygous carrier range, and 70–150 IU/dL as normal. A mixing test is performed at the same time: if the APTT is corrected (that is, falls into the normal range) after 1:1 mixing of patient plasma with normal plasma, factor deficiency is suggested; if not corrected, an inhibitor or lupus anticoagulant is suspected. Measuring FXI antigen (FXI:Ag) by ELISA or rocket electrophoresis allows type I (CRM−: both FXI:C and FXI:Ag reduced, FXI:C/FXI:Ag ratio ≈ 1) and type II (CRM+: normal FXI:Ag but reduced FXI:C, FXI:C/FXI:Ag ratio <0.5) to be distinguished from the ratio to FXI:C.

Laboratory differentiation from hemophilia A and B

Because both hemophilia A and hemophilia C show isolated APTT prolongation, differentiating the two at the laboratory stage is essential. Hemophilia C can be confirmed when single-factor FVIII:C is normal and FXI:C is reduced. Hemophilia B (FIX deficiency) also shows isolated APTT prolongation, so sequential measurement of FVIII:C, FIX:C, and FXI:C is recommended to clearly identify the factor responsible for APTT prolongation. FXII deficiency, PK deficiency, and HMW kininogen deficiency are conditions that prolong the APTT without clinical bleeding, and FXII:C, PK:C, and HMW kininogen:Ag are measured to differentiate them. In FXII deficiency, the APTT tends to shorten as the plasma contact activation time is lengthened, which is sometimes used for differentiation.

Inhibitors and other abnormal findings

Inhibitors to FXI (alloantibodies) are relatively rare in hemophilia C, but cases have been reported in the UK, Israel, and elsewhere, mainly after administration of FXI concentrates or large volumes of FFP. Patients homozygous for E117X have never been exposed to FXI protein and have not developed immune tolerance, so their risk of inhibitor development is relatively high. When an inhibitor develops, the APTT is not corrected after 2 hours of incubation at 37°C in the mixing test, and the inhibitor titer can be quantified as a Bethesda titer. Inhibitor development makes conventional FXI replacement difficult and complicates management. Also, when lupus anticoagulant (LA) happens to coexist in a patient with hemophilia C, the APTT may fail to correct in the mixing test, causing confusion, so additional tests to differentiate LA are needed.


8. Screening

Detection on preoperative coagulation testing

Many patients with hemophilia C are first suspected when APTT prolongation is incidentally found on routine preoperative coagulation screening. Because spontaneous bleeding is rare, a particularly common pattern is that patients reach adulthood without recognizing their bleeding disorder, and the abnormality is first found on tests done before general anesthesia or an invasive procedure. For this reason, referral by the anesthesiologist or surgeon to a hematologist for a patient with preoperative APTT prolongation becomes the first gateway to diagnosis. Note that the APTT reagents used in some hospitals have low sensitivity and may report mild FXI deficiency (at the level of heterozygous carriers) as normal. Therefore, if the surgical site is a high-risk area (oral, urologic, uterine), direct measurement of FXI:C should be considered in patients with a bleeding history even if the APTT is normal.

Clinical history-taking centered on bleeding history

Because hemophilia C can be asymptomatic even with low FXI:C, it is difficult to judge the need for treatment from laboratory tests alone. Systematic bleeding history-taking is therefore one of the most important screening tools. Ask systematically about past delayed bleeding after tooth extraction, unexpected excessive bleeding after surgery, frequency and duration of nosebleeds, excessive bruising, menstrual cycle and flow, and bleeding during pregnancy and delivery. Using the ISTH-BAT (International Society on Thrombosis and Haemostasis Bleeding Assessment Tool), this information can be scored and used for clinical decision-making. An abnormal BAT score (≥4 in adult men, ≥6 in adult women) is an indication for further coagulation testing.

Special features of family screening

Because hemophilia C is autosomal recessive, screening of all immediate family members is recommended once a patient is diagnosed. The patient's parents are mostly heterozygous carriers, and their FXI:C is also reduced to about 40–60%, so they need to be aware of this before any surgery. In the patient's siblings and children, APTT and FXI:C are measured, and if the familial variant is identified, F11 variant-specific testing is performed. In Ashkenazi Jewish families, rapid genetic testing for the two variants E117X and F283L allows efficient screening for carriers in the family. In particular, for carrier couples planning a pregnancy, prenatal genetic counseling is essential when both are confirmed carriers.

The paradoxical relationship with thrombosis risk and a new screening paradigm

An interesting clinical observation in patients with hemophilia C is that, despite their bleeding tendency, they have fewer hospitalizations for venous thromboembolism than the general population. This is because FXI contributes not only to hemostasis but also to thrombus formation. In clinical practice, this paradox becomes a factor to consider when deciding on anticoagulant administration for postoperative thromboprophylaxis. Giving anticoagulants for thromboprophylaxis to hemophilia C patients at high bleeding risk can worsen bleeding, so thromboprophylaxis strategies in orthopedic surgery or prolonged immobilization need to be individualized. When thrombosis risk is high and FXI deficiency is also present, mechanical prophylaxis (compression stockings, intermittent pneumatic compression devices) is recommended as the first choice.


9. Diagnosis

Stepwise diagnostic approach

Hemophilia C is confirmed according to a stepwise testing algorithm starting from clinical suspicion. Step 1: Confirm the pattern of isolated APTT prolongation on the routine coagulation screening panel (PT, APTT, TT, fibrinogen, platelet count). Normal PT and TT with prolonged APTT only suggest deficiency of an intrinsic pathway factor or an abnormality of the contact activation system. Step 2: Use a mixing test to differentiate factor deficiency (corrected after mixing) from an inhibitor/LA (fails to correct after mixing). Step 3: Measure contact activation factors by one-stage assays (FVIII:C, FIX:C, FXI:C, FXII:C, PK:C, HMW kininogen:Ag) to identify the deficient factor. Step 4: If FXI:C is reduced, measure FXI:Ag to distinguish type I (CRM−) from type II (CRM+). Step 5: Identify pathogenic variants by F11 gene analysis (Sanger sequencing or a rare hematologic disease NGS panel) and use the results for family screening and prenatal diagnosis.

Practical considerations in FXI:C testing

There are several practical considerations when measuring FXI:C by a one-stage clotting assay. First, sensitivity to FXI deficiency varies with the type of APTT reagent, and mild deficiency may be reported as normal, so it is necessary to know the characteristics of the laboratory's APTT reagent. Second, if plasma is not separated immediately after the sample is collected, FXI:C may be measured lower than it actually is. Third, in patients receiving warfarin or heparin, the APTT may be prolonged by the anticoagulant, raising the possibility of overdiagnosis or misdiagnosis of FXI deficiency, so retesting after stopping the drug or neutralization is needed. Fourth, because FXI:C rises slightly physiologically during pregnancy, values measured during pregnancy may be higher than when not pregnant, and interpretation requires caution.

Molecular diagnosis and variant databases

F11 gene variant analysis is central to definitive diagnosis, carrier diagnosis, family screening, and prenatal diagnosis. Variants are classified according to the ACMG/AMP 2015 guidelines with reference to ClinVar, HGMD (Human Gene Mutation Database), and coagulation factor-specific databases (e.g., the FXI module of HAMSTeRS). They are classified as pathogenic, likely pathogenic, of uncertain significance (VUS), likely benign, or benign, and variants classified as VUS (Variant of Uncertain Significance) are reclassified where possible through additional functional studies, segregation analysis, and in silico prediction. Because there is not yet a dedicated database of Korean F11 variants, a national-level collaborative system is needed to support pathogenicity classification of rare Korean variants through international databases and specialist society networks.

Summary of differential diagnosis

The main conditions to be differentiated from hemophilia C, with their clinical features, are summarized as follows. FVIII deficiency (hemophilia A): APTT prolonged, bleeding present, X-linked recessive, FVIII:C decreased. FIX deficiency (hemophilia B): APTT prolonged, bleeding present, X-linked recessive, FIX:C decreased. FXII deficiency: APTT very markedly prolonged, no bleeding, FXII:C decreased. PK deficiency: APTT prolonged (shortens with longer activation time), no bleeding. HMW kininogen deficiency: APTT prolonged, no bleeding. vWD type 2N: APTT mildly prolonged, FVIII:C decreased, vWF:RCo normal, abnormal vWF-FVIII binding assay. Lupus anticoagulant: APTT prolonged, fails to correct on mixing, thrombotic tendency. Performing this differential diagnosis systematically allows hemophilia C to be diagnosed accurately and prevents unnecessary treatment or misjudgment of surgical risk.


10. Treatment

Principles of individualized treatment based on bleeding history

Unlike hemophilia A and B, the core principle of treatment for hemophilia C is an individualized approach based on the patient's bleeding history rather than the FXI:C level. Even with severe deficiency with FXI:C near 0, prophylactic treatment is not needed in asymptomatic patients who have never undergone surgery or trauma. Conversely, even heterozygous carriers (FXI:C about 40–60%) need prophylactic treatment for the next procedure if they have experienced abnormal bleeding at past tooth extractions or surgery. Risk stratification by type of procedure is also important. For procedures at sites with very high fibrinolytic activity (oral cavity, tonsils, urinary tract, uterus), prophylactic tranexamic acid is recommended even if FXI:C is relatively good, while for procedures in deep tissues (muscle, joints, thoracic and abdominal cavities), the decision is made by combining FXI:C and bleeding history.

Fresh frozen plasma (FFP) and FXI concentrates

The first treatment option for hemophilia C is fresh frozen plasma (FFP), the most widely available worldwide. It is usually given intravenously at a dose of 15–20 mL/kg; the target FXI:C varies with the type of procedure but is generally 70 IU/dL or higher around high-risk surgery and 45–50 IU/dL or higher for low-risk procedures. The disadvantages of FFP are transfusion volume overload, allergic reactions, and a small residual risk of infection transmission. FXI concentrates (plasma-derived) are available in some countries, such as the UK (BPL FXI concentrate), France, and Israel, and can achieve higher FXI:C with a small volume. However, because they carry a risk of inducing thrombosis, caution is needed especially when used during postoperative immobility, and repeated administration carries a risk of inhibitor development. They are currently not commercially available in Korea.

Tranexamic acid: a key adjunct in the treatment of hemophilia C

Tranexamic acid (TXA) holds a particularly important place in the treatment of hemophilia C. Tranexamic acid is an antifibrinolytic that inhibits the conversion of plasminogen to plasmin and is especially effective for bleeding at sites with high fibrinolytic activity, such as the oral cavity, urinary tract, and uterus. In patients with hemophilia C, combining oral administration before tooth extraction with topical rinsing (mouthwash) can often effectively prevent post-extraction bleeding even without FFP. In menorrhagia, daily oral use during the menstrual period can significantly reduce menstrual flow. The usual adult oral dose is 15–25 mg/kg (standard 500–1,000 mg) 2–3 times a day during the period of bleeding risk. Intravenous administration is also possible, and topical application to the postoperative wound site has also been studied. In urinary tract bleeding, its use should be avoided or cautious because of the risk of urinary tract obstruction.

Bypassing therapy when inhibitors develop

In the rare patients who develop inhibitors to FXI, FFP and FXI concentrates lose their effect, so bypassing agents are used. Recombinant activated factor VII (rFVIIa, NovoSeven) at very high concentrations bypasses the FXI pathway and generates thrombin through direct generation of FXa and the prothrombinase complex. Activated prothrombin complex concentrate (aPCC, FEIBA) can also be used through a similar bypassing mechanism. Clinical experience with both agents in FXI-deficient patients with inhibitors is limited compared with hemophilia A and B, and their use is based mainly on individual case reports. When the inhibitor titer is high, combination with immunosuppression (prednisolone, rituximab, etc.) is sometimes attempted, but no standardized immune tolerance protocol has been established.


11. Prognosis

Long-term prognosis superior to hemophilia A and B

With appropriate medical management, the long-term prognosis of hemophilia C (hereditary factor XI deficiency) allows a normal life expectancy and is generally better than that of hemophilia A and B. In severe hemophilia A and B left without prophylaxis, recurrent spontaneous joint bleeding can lead to progressive hemophilic arthropathy, resulting in permanent joint destruction and disability. In contrast, because spontaneous deep bleeding almost never occurs in hemophilia C, chronic musculoskeletal complications such as arthropathy and muscle atrophy do not occur. Accordingly, orthopedic treatment or physical therapy is rarely needed, and growth disorders due to abnormal joint development are not observed in growing children. Unlike hemophilia A and B, in which HIV and HCV infections from contaminated transfused blood in the 1980s caused a great tragedy in the patient population, hemophilia C is treated with FFP, but safety has now been greatly improved by pathogen inactivation.

Preventability of surgery-related bleeding complications

The most important risk factor for prognosis in patients with hemophilia C is abnormal bleeding during surgery or procedures performed before the condition has been diagnosed. In particular, when unexpected bleeding complications occur during oral, tonsillar, urologic, or uterine procedures with high fibrinolytic activity, they are not infrequently life-threatening. Conversely, when hemophilia C has been diagnosed beforehand and appropriate prophylactic treatment (FFP, tranexamic acid, etc.) is planned and given in consultation with a hematologist, most patients recover successfully from surgery without bleeding complications. This shows clearly how important early diagnosis and patient education are for improving prognosis. After diagnosis, self-management habits—always carrying a medical alert card and informing non-hematology physicians such as dentists, surgeons, and obstetrician-gynecologists of one's condition in advance—are key to preventing unexpected bleeding complications.

The future of new FXI-targeted therapies and their significance for patients with hemophilia C

Anti-FXI/FXIa agents currently in clinical development are, paradoxically, also an issue affecting patients with hemophilia C. If these drugs are given to hemophilia C patients for atrial fibrillation or stroke prevention, additional FXI inhibition on top of already reduced FXI function could cause more serious bleeding. Clinicians need to be especially cautious when giving these new antithrombotic agents to patients with hemophilia C, and consultation with a hematologist before administration is essential. At the same time, long-term follow-up cohort data on FXI levels and thrombotic and bleeding experiences in patients with hemophilia C may serve as a valuable reference for understanding the safety profile of these new drugs.

Prognosis in female patients and in pregnancy

In women with hemophilia C, menorrhagia and postpartum hemorrhage are important factors that worsen prognosis. However, menorrhagia can be effectively controlled with appropriate drug treatment (tranexamic acid, oral contraceptives, hormonal intrauterine devices), and postpartum hemorrhage can also be prevented when the delivery plan is well established. Pregnancy and delivery outcomes in women with hemophilia C are generally good under specialized multidisciplinary management. Because intracranial hemorrhage after delivery has rarely been reported in newborns found to have FXI deficiency, when both parents are carriers it is recommended to test the newborn's FXI:C after delivery and to take care with invasive procedures (scalp electrodes, vacuum delivery, etc.).


12. Prevention

Genetic counseling and prenatal diagnosis

When a patient with hemophilia C or a carrier is identified, specialized genetic counseling is essential. Genetic counseling should thoroughly discuss the principles of autosomal recessive inheritance, the risk of an affected child (25% when both parents are heterozygous carriers), the clinical significance of heterozygous carriers, and the availability of prenatal diagnosis and preimplantation genetic testing. In particular, for people of Ashkenazi Jewish background, screening for the F11 E117X and F283L variants is recommended before marriage or when planning a pregnancy. Prenatal diagnosis is performed by analyzing the fetal F11 gene through chorionic villus sampling (CVS) at 10–12 weeks of gestation or amniocentesis at 14–18 weeks of gestation, and preimplantation genetic testing (PGT-M) can be considered as an option, combined with an in vitro fertilization (IVF) cycle, to prevent implantation of affected embryos. However, considering that hemophilia C does not shorten life expectancy and that most bleeding is preventable, all decisions should be made with respect for the couple's values and informed choice.

Preventive planning before surgery and procedures

The most effective measure to prevent bleeding complications in patients with hemophilia C is prior consultation with a hematologist before any invasive procedure. As soon as a procedure is planned, it is essential to refer to hematology to confirm the latest FXI:C measurement, review the past bleeding history, assess the level of fibrinolytic activity at the procedure site, and establish a treatment plan according to the scale of the procedure (whether to use FFP, tranexamic acid dose and duration, timing of start and end of administration). Even minor procedures at high-risk sites such as tooth extraction, tonsillectomy, uterine procedures, and urologic procedures require a specific hemostatic plan including prophylactic tranexamic acid. Patients should always carry information on their coagulation status via a medical alert card or smartphone application so that a hematologist can be contacted immediately even when emergency surgery is needed.

Precautions for daily life

The recommended precautions in daily life for patients with hemophilia C are as follows. First, aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) increase bleeding risk by inhibiting platelet function, so acetaminophen is used first instead of ibuprofen or naproxen for routine pain and fever. When there is a risk of dental bleeding, a plan to stop antiplatelet agents in advance is made in consultation with the physician. Second, when anticoagulants (warfarin, DOAC) are needed for other indications, the minimum effective dose balancing bleeding and thrombosis is determined in close consultation with a hematologist. Third, unlike hemophilia A and B, patients with hemophilia C can participate in most sports and physical activities without restriction, but wearing protective equipment is recommended in sports with a high risk of falls or collisions. Fourth, always carry a medical alert card (wallet type or smartphone app) so that hemophilia C status can be communicated immediately to medical staff in an emergency.

Prevention in special situations

Preventive measures for situations requiring special attention in patients with hemophilia C are described as follows. Pregnancy and delivery: Register with a multidisciplinary hematology–obstetrics team in early pregnancy to establish a delivery plan. Check FXI:C before epidural anesthesia, and consider bleeding risk when deciding the mode of delivery (vaginal vs cesarean section). Prepare FFP and tranexamic acid before delivery, and monitor FXI:C for 48–72 hours postpartum. Pediatric vaccination: Administer subcutaneously rather than intramuscularly, or minimize bleeding by applying sufficient pressure after injection. Emergencies: In massive bleeding or severe trauma, administer FFP promptly, and if surgery is unavoidable, request immediate hematology consultation. When traveling long distances, it is safe to have the contact information of the treating hematologist and information on medical institutions able to transfuse FFP ready in advance.


13. References

  1. Rosenthal RL, Dreskin OH, Rosenthal N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med. 1953;82(1):171–174.
  2. Bolton-Maggs PHB, Patterson DA, Wensley RT, Tuddenham EGD. Definition of the bleeding tendency in factor XI-deficient kindreds—a clinical and laboratory study. Thromb Haemost. 1995;73(2):194–202.
  3. Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med. 1991;325(3):153–158.
  4. Seligsohn U. Factor XI in haemostasis and thrombosis: past, present and future. Thromb Haemost. 2007;98(1):84–89.
  5. Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost. 2013;39(6):621–631.
  6. Gomez K, Bolton-Maggs P. Factor XI deficiency. Haemophilia. 2008;14(6):1183–1189.
  7. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342(10):696–701.
  8. Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372(3):232–240.
  9. Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European network of rare bleeding disorders. J Thromb Haemost. 2012;10(4):615–621.
  10. Salomon O, Steinberg DM, Dardik R, et al. Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost. 2003;1(4):658–661.
  11. Gailani D, Renné T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(12):2507–2513.
  12. Zadra G, Asselta R, Tenchini ML, et al. Cloning and characterization of the human factor XI gene region. Nucleic Acids Res. 1991;19(13):3591.